Rexmyelocel T

N/A

Report date: 2023/03/17 20:00:39

Base Information

Drug NameRexmyelocel T

Drug Alias NameBM-MNCs - RexgeneroBone-marrow-derived-mononuclear-cells-RexgeneroREX-001

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy

Mechanisms of ActionHaematopoiesis stimulantsStem cell replacements

TargetsNot applicable

Therapy Area/IndicationsIschemiaDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1 +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaPolandPortugal +[8]

CombinationsNo

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesRexgenero Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesIxaka Ltd

Active IndicationsN/A

Inactive IndicationsIschemiaDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1 +[6]

Other Information

ATC CodeN/A